Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines

Patient concerns over ever-increasing costs are growing, especially when it comes to their health care. Morning Consult recently conducted a 50-state poll of 20,000 Americans on behalf of PhRMA to...
Read More
New poll shows voters sounding the alarm on health insurance companies and PBMs

Many Americans battle with an illness every day, but unfortunately for some, their illness is not the only battle they face. A recent Morning Consult/PhRMA poll of 2,004 registered voters shows that...
Read More
In comments to federal agency, PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for prescription medicines

In comments submitted to the Federal Trade Commission (FTC), PhRMA urged the agency to examine how pharmacy benefit managers (PBMs) leverage their extraordinary power to maximize profits, often in...
Read More
Government price setting won’t stop insurers from shifting costs to patients

The drug pricing provisions in the Build Back Better Act (BBBA) would allow the government to set the price of certain medicines in Medicare. This is a misguided approach that threatens future...
Read More
New insulin report highlights how incentives benefit middlemen, harm patients

The Senate Finance Committee has released a new report detailing findings of their investigation into the role that market dynamics play in the pricing of insulins. The report conclusions further...
Read More
Key facts: The final rebate rule will be a positive change for patients

While drug middlemen are making billions of dollars in record profits at a time when millions of Americans are facing financial struggles, they are also suing to block the final rebate rule, a policy...
Read More
PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients

In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander, PhRMA has outlined a number of commonsense ways...
Read More
Study finds middlemen excluded nearly 850 medicines from formularies this year

A new study from Xcenda finds that from 2014 to 2020, the number of medicines excluded by at least one of the three largest pharmacy benefit managers (PBMs) from their standard formularies increased...
Read More
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs

Yesterday, PhRMA submitted comments on the Department of Health & Human Services’ (HHS) 2021 Notice of Benefit and Payment Parameters proposed rule. The proposed rule would hurt patients’ ability to...
Read More
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients

Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients....
Read More